EP0935600A1 - Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte - Google Patents

Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte

Info

Publication number
EP0935600A1
EP0935600A1 EP97913157A EP97913157A EP0935600A1 EP 0935600 A1 EP0935600 A1 EP 0935600A1 EP 97913157 A EP97913157 A EP 97913157A EP 97913157 A EP97913157 A EP 97913157A EP 0935600 A1 EP0935600 A1 EP 0935600A1
Authority
EP
European Patent Office
Prior art keywords
formulas
chlorine
alkyl
compound
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97913157A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stefan Antons
Reinhold Gehring
Tim Bielfeldt
Bernhard Beitzke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996143826 external-priority patent/DE19643826A1/de
Priority claimed from DE19648214A external-priority patent/DE19648214A1/de
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP0935600A1 publication Critical patent/EP0935600A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals

Definitions

  • the present invention relates first of all to an advantageous process for the preparation of the naphthyridine compounds characterized by formulas (Ia) to (Ic) below and to new intermediates which are key compounds for this process.
  • Naphthyridine compounds of the formulas (Ia) to (Ic) are valuable intermediates for the preparation of active compounds, in particular highly effective bactericides (see, for example, US Pat. No. 5,164,402, US Pat. No. 5,298,629 and EP-OS 413 455).
  • naphthyridine compounds of the formula (Ia) by reacting a halogenated nicotinoyl chloride with a malonic ester, then decarboxylating one of the two carboxylate groups, then converting the methylene group between the two carbonyl groups into an using an ortho-ester
  • R represents hydrogen or C r C 4 alkyl
  • n 1, 2 or 3, found
  • R 1 represents C r C 4 alkyl
  • R and R independently of one another represent C j -C 6 alkyl, where the alkyl chain can in each case optionally be interrupted by O, S or NH,
  • R ', R 1 and R 2 have the meaning given for formula (III),
  • Ar has the meaning given in the formulas (la) to (Ic)
  • Ar, n and shark are those given in formulas (la) to (Ic),
  • R and to the extent that R is C 1 -C 4 -alkyl can each be straight-chain or branched and can be, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl.
  • R preferably represents hydrogen, methyl or ethyl.
  • R preferably represents methyl or ethyl.
  • the substituents can be, for example
  • Ar is preferably phenyl, 2,4-difluorophenyl, 2-fluorophenyl or 4-fluorophenyl.
  • Shark is preferably fluorine or chlorine. When there are two sharks, one is preferably fluorine and the other is chlorine. When there are three sharks, 1 to 2 are preferably fluorine and the rest are chlorine. It is further preferred that a fluorine substituent is located on the carbon atom in the meta position to the carbonyl group (this is the 6 position in formula (Ia) and the corresponding position in the other formulas).
  • Hai ' is preferably chlorine, n is preferably 2.
  • R 1 and R 2 are preferably the same and each represent methyl or ethyl, in particular ethyl.
  • the reaction of compounds of the formulas (Ha) to (IIc) with a compound of the formula (III) can be carried out, for example, by initially introducing the compound of the formula (III), a solvent and a base and a compound of the formulas (Ha ) to (IIc).
  • the reactants can be used in any ratio to one another.
  • the molar ratio of the compound of the formulas (Ha) to (IIc) to the compound of the formula (III) is preferably 0.8 to 1.2: 1, in particular 0.9 to 1.1: 1.
  • inorganic and organic bases can be used as bases.
  • bases which are sparingly soluble in the reaction mixture for example inorganic bases
  • a phase transfer catalyst for example inorganic bases
  • Organic bases for example amines
  • Tertiary amines which contain, for example, three identical or different C 1 -C 6 -alkyl groups such as triethylamine are particularly preferred.
  • the amount of base should be at least the stoichiometrically required amount, a small excess is preferred, for example up to 120% by weight of the stoichiometrically required amount.
  • chlorinated hydrocarbons and aromatics are suitable as solvents.
  • reaction temperature can be, for example, in the range from -10 to + 80 ° C. In general, it is advantageous to stir at the reaction temperature for a while after the reactants have been combined.
  • the overall process for the preparation of naphthyridine compounds of the formulas (Ic) to Ic) can be carried out in the reactor in which the fully reacted reaction mixture of reacting a compound of the formulas (Ila) to (IIc) with a compound of the formula (III) is present. Isolation of the compound of the formulas (IVa) to (IVc) produced is not necessary for this.
  • reaction of a compound of the formulas (IVa) to (IVc) with a compound of the formula (V) to a compound of the formulas (Via) to (VIc) can be carried out e.g. carry out such that a compound of the formulas (IVa) to (IVc), preferably in the form of the fully reacted reaction mixture obtained in its preparation, is acidified and at temperatures of, for example, below
  • (V) preferably 0.8 to 1.2: 1, in particular 0.9 to 1.1: 1.
  • inorganic and organic acids can be used for acidification.
  • the amount of acid can be chosen, for example, so that there is a slight excess with respect to the base used. The amount of acid can thus be, for example, up to 125 equivalent%, based on the base used.
  • the laundry can e.g. at temperatures from room temperature to 95 ° C.
  • the dipolar aprotic solvent can be, for example, dimethylformamide, dimethyl sulfoxide, tetramethylene sulfone or N-methylpyrrolidone.
  • Suitable acid scavengers are alkali metal salts such as alkali metal fluorides, carbonates, bicarbonates and hydrides. The following may be mentioned as individual examples: sodium fluoride, sodium hydride, sodium carbonate, sodium bicarbonate, potassium fluoride and potassium bicarbonate. It is advantageous to use the acid scavenger in an excess, for example in an excess of 10 to 50% by weight, based on the theoretical required amount. It is also advantageous to carry out the cyclization under as anhydrous conditions as possible.
  • an aqueous acid can be added until a pH e.g. in the
  • naphthyridine compounds of the formulas (la) to (Ic) in purities of over 99%, often over 99.8%, and in yields (based on halogenated acid chloride of the formulas (I ⁇ a) to (IIc)) of over 80% d. Th. Received.
  • the process according to the invention is advantageous not only because of these good results in terms of yield and purity, but also because it is particularly simple, requires only two reaction vessels and delivers highly pure products without the isolation of intermediate stages. In view of the prior art described at the outset, this is extremely surprising.
  • n 1, 2 or 3
  • Ar represents optionally substituted phenyl.
  • Example 2 The procedure was first as in Example 2. The washed toluene solution obtained there was metered in over 3 hours onto a template heated to 60 ° C. from 250 ml of N-methylpyrrolidone and 28 g of anhydrous potassium carbonate. At the same time, toluene was continuously distilled off in vacuo.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP97913157A 1996-10-30 1997-10-17 Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte Withdrawn EP0935600A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19643826 1996-10-30
DE1996143826 DE19643826A1 (de) 1996-10-30 1996-10-30 Verfahren zur Herstellung von Naphthyridinverbindungen und neue Zwischenprodukte
DE19648214A DE19648214A1 (de) 1996-11-21 1996-11-21 Verfahren zur Herstellung von Naphthyridinverbindungen und neue Zwischenprodukte
DE19648214 1996-11-21
PCT/EP1997/005743 WO1998018795A1 (de) 1996-10-30 1997-10-17 Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte

Publications (1)

Publication Number Publication Date
EP0935600A1 true EP0935600A1 (de) 1999-08-18

Family

ID=26030644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97913157A Withdrawn EP0935600A1 (de) 1996-10-30 1997-10-17 Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte

Country Status (10)

Country Link
EP (1) EP0935600A1 (ja)
JP (1) JP2001502715A (ja)
KR (1) KR20000052892A (ja)
CN (1) CN1235605A (ja)
AU (1) AU5050898A (ja)
CA (1) CA2269984A1 (ja)
CZ (1) CZ154999A3 (ja)
IL (1) IL129597A0 (ja)
PL (1) PL332941A1 (ja)
WO (1) WO1998018795A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001054A3 (en) 1997-08-06 2001-01-29 Daiichi Asubio Pharma Co Ltd 1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS274601B2 (en) * 1983-07-27 1991-09-15 Dainippon Pharmaceutical Co Method of 1,8-naphthyridine derivative production
JPS60228479A (ja) * 1984-04-26 1985-11-13 Toyama Chem Co Ltd 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩
DE4425647A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Heterocyclyl-1-phenyl substituierte Chinoloncarbonsäuren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9818795A1 *

Also Published As

Publication number Publication date
CA2269984A1 (en) 1998-05-07
AU5050898A (en) 1998-05-22
IL129597A0 (en) 2000-02-29
PL332941A1 (en) 1999-10-25
JP2001502715A (ja) 2001-02-27
CN1235605A (zh) 1999-11-17
CZ154999A3 (cs) 1999-08-11
KR20000052892A (ko) 2000-08-25
WO1998018795A1 (de) 1998-05-07

Similar Documents

Publication Publication Date Title
DE2914494C2 (ja)
DE69723846T2 (de) Verfahren zur Herstellung von Sildenafil
EP0039844A2 (de) Verfahren zur Herstellung von O-substituierten Derivaten des (+)-Cyanidan-3-ols
CH639662A5 (de) Imidazoazine und imidazodiazine.
DE2655009C2 (ja)
DE69837100T2 (de) Verfahren zur synthese von chinolinderivaten
DE69826845T2 (de) Verfahren zur herstellung von arylsulfonylchlorid
EP0017181A1 (de) Neues Verfahren zur Herstellung von Imidazobenzodiazepinderivaten sowie Zwischenprodukte zu deren Herstellung
WO1998018795A1 (de) Verfahren zur herstellung von naphthyridinverbindungen und neue zwischenprodukte
EP1685098B1 (de) Ortho-substituierte pentafluorsulfanyl-benzole, verfahren zu ihrer herstellung sowie ihre verwendung ais wertvolle synthese-zwischenstufen
DE2633992A1 (de) Neue pyrazol-derivate, ihre herstellung und verwendung
EP0693466B1 (de) Verfahren zur Herstellung von aromatischen fluorierten Verbindungen und neue Diamide
EP0453885A2 (de) Verfahren zur Herstellung aromatischer Amine
EP0091044B1 (de) Verfahren zur Herstellung von 4-Hydroxy-3-(heterocyclocarbamoyl)-2H-1,2-benzothiazin-1,1-dioxiden
DE19643826A1 (de) Verfahren zur Herstellung von Naphthyridinverbindungen und neue Zwischenprodukte
DE2245363A1 (de) Pyridopyrimidone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CH627430A5 (en) Process for preparing alpha -ketocarboxylic acids
EP0004322A1 (de) Isochinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19648214A1 (de) Verfahren zur Herstellung von Naphthyridinverbindungen und neue Zwischenprodukte
DE3153481C2 (de) Zwischenstufen zur Herstellung herbizid wirksamer 2-(2-Imidazolin-2-yl)-pyridine und -chinoline
DE4208778C1 (ja)
EP0341478A2 (de) Verfahren zur Herstellung von 2,3-Dichlor-5-acetylpyridin
DE69928107T2 (de) Heterozyklus mit thiophenol gruppe, intermediate zur herstellung und herstellungsverfahren für beide stoffgruppen
DE2353580C2 (de) Verfahren zur Herstellung von o-Acylamino-diarylverbindungen
EP0420815B1 (de) Verfahren zur Herstellung von 2-(2-Halogenethylthio)-phenylsulfonamiden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FI FR GB IE IT LI NL PT

AX Request for extension of the european patent

Free format text: SI PAYMENT 19990531

17Q First examination report despatched

Effective date: 20000126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20000714